肠道菌群经TLR4信号通路调控低糖基化IgA1生成参与IgA肾病
该研究纳入48例未治疗IgA肾病、22例治疗IgA肾病、22例原发性膜性肾病和31例健康对照,分析肠道菌群与Gd-IgA1及TLR4通路的关系。未治疗IgA肾病患者存在肠道菌群失调,Gd-IgA1升高且与菌群失调、TLR4、B细胞刺激因子及肠道屏障损伤相关。小鼠粪菌移植和体外实验表明,肠道菌群失调经TLR4/MyD88/NF-κB通路及B细胞刺激因子促进Gd-IgA1过度生成,TLR4抑制剂可抑制该过程。
要点
- 未治疗IgA肾病患者存在肠道菌群失调,多样性下降,埃希菌-志贺菌属富集。
- Gd-IgA1升高与肠道菌群失调、TLR4、B细胞刺激因子及肠道屏障损伤相关。
- TLR4抑制剂可抑制LPS诱导的Gd-IgA1过度生成,提示TLR4通路为潜在干预靶点。
核心结论
- 肠-肾轴参与IgA肾病发病,肠道菌群失调经TLR4信号通路及B细胞刺激因子促进Gd-IgA1过度生成。
研究设计与样本
- 研究纳入48例未治疗IgA肾病、22例治疗IgA肾病、22例原发性膜性肾病和31例健康对照,分析粪便菌群、Gd-IgA1、TLR4及肠道屏障功能。
- 采用广谱抗生素清除肠道菌群的小鼠,接受各组临床受试者粪菌移植,检测Gd-IgA1及TLR4通路。
- 体外将IgA肾病患者与健康对照外周血单个核细胞与LPS及TLR4抑制剂共孵育,检测TLR4通路及Gd-IgA1。
主要发现
- 与其余三组相比,未治疗IgA肾病组肠道菌群组成不同、多样性下降,以埃希菌-志贺菌属富集为特征。
- 未治疗IgA肾病患者Gd-IgA1水平升高,且与肠道菌群失调、TLR4、B细胞刺激因子、肠道屏障损伤指标及促炎细胞因子相关。
- 接受IgA肾病或治疗IgA肾病患者粪菌移植的小鼠出现IgA肾病表型,肠道TLR4/MyD88/NF-κB通路及B细胞刺激因子激活,促炎细胞因子增强。
- 体外LPS激活IgA肾病患者外周血单个核细胞TLR4/MyD88/NF-κB通路、B细胞刺激因子及促炎细胞因子,可能诱导Gd-IgA1过度生成,TLR4抑制剂可抑制该过程。
临床怎么用
- 肠道菌群失调与Gd-IgA1升高相关,提示调节肠道菌群或靶向TLR4通路可能成为IgA肾病潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is a major cause of primary glomerulonephritis characterized by mesangial deposits of galactose-deficient IgA1 (Gd-IgA1). Toll-like receptors (TLRs), particularly TLR4, are involved in the pathogenesis of IgAN. The role of gut microbiota on IgAN patients was recently investigated. However, whether gut microbial modifications of Gd-IgA1 through TLR4 play a role in IgAN remains unclear. METHODS: We recruited subjects into four groups, including 48 patients with untreated IgAN, 22 treated IgAN patients (IgANIT), 22 primary membranous nephropathy and 31 healthy controls (HCs). Fecal samples were collected to analyze changes in gut microbiome. Gd-IgA1 levels, expression of TLR4, B-cell stimulators and intestinal barrier function were evaluated in all subjects. C57BL/6 mice were treated with a broad-spectrum antibiotic cocktail to deplete the gut microbiota and then gavaged with fecal microbiota transplanted from clinical subjects of every group. Gd-IgA1 and TLR4 pathway were detected in peripheral blood mononuclear cells (PBMCs) from IgAN and HCs co-incubated with lipopolysaccharide (LPS) and TLR4 inhibitor. RESULTS: Compared with the other three groups, different compositions and decreased diversity demonstrated gut dysbiosis in the untreated IgAN group, especially the enrichment of Escherichia-Shigella. Elevated Gd-IgA1 levels were found in untreated IgAN patients and correlated with gut dysbiosis, TLR4, B-cell stimulators, indexes of intestinal barrier damage and proinflammatory cytokines. In vivo, mice colonized with gut microbiota from IgAN and IgANIT patients mimicked the IgAN phenotype with the activation of TLR4/MyD88/nuclear factor-κB pathway and B-cell stimulators in the intestine, and had with enhanced proinflammatory cytokines. In vitro, LPS activated TLR4/MyD88/NF-κB pathway, B-cell stimulators and proinflammatory cytokines in PBMCs of IgAN patients. This process may induce the overproduction of Gd-IgA1, which was inhibited by TLR4 inhibitors. CONCLUSIONS: Our results illustrated that the gut-kidney axis is involved in the pathogenesis of IgAN. Gut dysbiosis could stimulate the overproduction of Gd-IgA1 via TLR4 signaling pathway production and B-cell stimulators.
引用
- Zhu Y, He H, Sun W, et al. IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway. Nephrol Dial Transplant. 2024. PMID: 38402460. doi:10.1093/ndt/gfae052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。